Kineta, Inc. (KANT)
OTCMKTS · Delayed Price · Currency is USD
0.2997
-0.0003 (-0.10%)
May 12, 2025, 4:00 PM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20
Next-generation Immunotherapies
5.44M
Log In
Log In
Log In
Next-generation Immunotherapies Growth
178.65%
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20
United States
5.44M
Log In
Log In
Log In
United States Growth
178.65%
Log In
Log In
Log In